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Abstract
Background and hypothesis: Based on neurochemical and genetic evidence, we suggest that
both prevention and treatment of multiple addictions, such as dependence to alcohol, nicotine and
glucose, should involve a biphasic approach. Thus, acute treatment should consist of preferential
blocking of postsynaptic Nucleus Accumbens (NAc) dopamine receptors (D1-D5), whereas long
term activation of the mesolimbic dopaminergic system should involve activation and/or release of
Dopamine (DA) at the NAc site. Failure to do so will result in abnormal mood, behavior and
potential suicide ideation. Individuals possessing a paucity of serotonergic and/or dopaminergic
receptors, and an increased rate of synaptic DA catabolism due to high catabolic genotype of the
COMT gene, are predisposed to self-medicating any substance or behavior that will activate DA
release, including alcohol, opiates, psychostimulants, nicotine, gambling, sex, and even excessive
internet gaming. Acute utilization of these substances and/or stimulatory behaviors induces a feeling
of well being. Unfortunately, sustained and prolonged abuse leads to a toxic" pseudo feeling" of well
being resulting in tolerance and disease or discomfort. Thus, a reduced number of DA receptors,
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due to carrying the DRD2 A1 allelic genotype, results in excessive craving behavior; whereas a
normal or sufficient amount of DA receptors results in low craving behavior. In terms of preventing
substance abuse, one goal would be to induce a proliferation of DA D2 receptors in genetically
prone individuals. While in vivo experiments using a typical D2 receptor agonist induce down
regulation, experiments in vitro have shown that constant stimulation of the DA receptor system
via a known D2 agonist results in significant proliferation of D2 receptors in spite of genetic
antecedents. In essence, D2 receptor stimulation signals negative feedback mechanisms in the
mesolimbic system to induce mRNA expression causing proliferation of D2 receptors.
Proposal and conclusion: The authors propose that D2 receptor stimulation can be
accomplished via the use of Synapatmine™, a natural but therapeutic nutraceutical formulation that
potentially induces DA release, causing the same induction of D2-directed mRNA and thus
proliferation of D2 receptors in the human. This proliferation of D2 receptors in turn will induce
the attenuation of craving behavior. In fact as mentioned earlier, this model has been proven in
research showing DNA-directed compensatory overexpression (a form of gene therapy) of the
DRD2 receptors, resulting in a significant reduction in alcohol craving behavior in alcohol preferring
rodents. Utilizing natural dopaminergic repletion therapy to promote long term dopaminergic
activation will ultimately lead to a common, safe and effective modality to treat Reward Deficiency
Syndrome (RDS) behaviors including Substance Use Disorders (SUD), Attention Deficit
Hyperactivity Disorder (ADHD), Obesity and other reward deficient aberrant behaviors. This
concept is further supported by the more comprehensive understanding of the role of dopamine
in the NAc as a "wanting" messenger in the meso-limbic DA system.
Background
It is well known that brain reward circuitry is regulated by
neurotransmitter interactions and net release of the sub-
stance Dopamine (DA) in the Nucleus accumbens (NAc)
[1]. The major loci for feelings of well-being and reward
occur in the meso-limbic system of the brain. The natural
sequence of events of the "brain reward cascade" leading
to reward involves the inter-relationship of at least four
important neurochemical pathways: serotonergic (5-HT);
enkephalinergic (Enk), GABAergic (GABA), and
dopaminergic (DA). The synthesis, vesicle storage, metab-
olism, release and function of these neurotransmitters are
regulated by genes and the expression thereof in terms of
messenger RNA (mRNA) directed proteins. It has been
postulated that genome orientated research will provide
genetic testing that will categorize individuals as to their
specific neurochemical makeup and thus provide useful
information to assist in appropriate development of the
most correct treatment options for the patient requiring
psychiatric care [2]. DA is a substance with many impor-
tant neurochemical functions and has been credited with
resultant behavioral effects such as "pleasure," "stress
reduction" and "wanting". Simply stated, without the nor-
mal functionality of DA, an individual will be lacking
hedonic response and an inability to cope with stress [3].
Thus genetic hypodopaminergic activity of the brain pre-
disposes an individual to seek substances and/or behav-
iors that will overcome this anhedonic state by activating
meso-limbic dopaminergic centers [4]. It turns out that
these substances and behaviors include: alcohol, opiates,
psychostimulants, nicotine, carbohydrates, cannabinoids,
gambling, sex, and indulgence in any excessive pleasure or
thrill seeking behaviors, like video gaming etc. [5-16]. Use
of these substances and engaging in these aforementioned
behaviors commonly induces the release of neuronal DA
into the synapse at the NAc, the reward center of the brain
[3]. Acute indulgence in these behaviors can be classified
as self-medicating and leads to a preferential release of
DA, which overcomes the hypodopaminergic state for
that individual. The resultant self-medication provides a
temporary relief of discomfort and a "pseudo feeling" of
well-being [17]. Unfortunately, chronic abuse of these
psychoactive substances and excessive indulgence in the
aberrant behaviors leads to inactivation of the brain
reward cascade (i.e. neurotransmitter synthesis inhibition,
neurotransmitter storage depletion, toxic formation of
pseudo neurotransmitters and receptor dysfunction
(structural and or density)). The abusive behaviors also
lead to neurotransmitter dysfunction via depletion. There-
fore both substance seeking and pathological behaviors as
ways of providing a feel good response (FGR) "fix" result
in ever escalating and uncontrollable craving behavior. It
has been well established that individuals possessing cer-
tain genetic polymorphisms (variations) are particularly
prone to amplified polymorphic expressions with envi-
ronmental or lifestyle insult and will be at increased risk
for impulsive, compulsive and addictive behaviors [18].
Such common genetic antecedents influencing the natural
brain reward cascade provide the understanding that
impulsive, compulsive and addictive behaviors are com-
monly linked and support the emerging concept of
Reward Deficiency Syndrome (RDS) as an umbrella termTheoretical Biology and Medical Modelling 2008, 5:24 http://www.tbiomed.com/content/5/1/24
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to characterize and classify these commonly linked genet-
ically induced behaviors [19-21]. In this scenario any and
all of these abusable psychoactive drugs or pathological
behaviors are candidates for addiction (tolerance/depend-
ence) and are chosen by the individual as a function of
both genes and environmental factors (e.g. availability,
peer pressure, etc.) [18].
Brain reward cascade explanation
While dopamine (DA) is critical to maintain normaliza-
tion of natural rewards, the neuronal release of DA into
NAc synaptic sites is somewhat complex. In 1989 our lab-
oratory proposed an interactive cascade of events of mes-
olimbic function that lead to net DA release [1]. It was
termed the "brain reward cascade' (see Figure 1)
The interactions of activities in the separate subsystems
mentioned above merge together into the much larger
global system. These activities take place simultaneously
and in a specific sequence, merging like a cascade. The end
result is a sense of peace, pleasure, and well-being when
these systems work normally. If there is a deficiency or
imbalance, the system works abnormally, causing the
sense of well-being to be displaced by feelings of anxiety,
anger, low self-esteem, and/or other "bad feelings"[15].
This can lead to cravings for substances and/or behaviors
that mask or relieve those bad feelings such as carbohy-
drate bingeing, alcohol, or cocaine; or to other addictive
behaviors such as compulsive gambling, compulsive sex,
workaholism, or engaging in high risk activities; all exces-
sive desires spurred by the need for a dopamine fix [19-
21].
Other research has confirmed that the reward sensation is
related to complex cascade reactions involving several
neurotransmitters and structures in the limbic system
[22]. The ultimate result of the process is the activation of
the meso-limbic dopamine pathway, which starts in the
tegmental ventral area and ends at the dopamine D2
receptors on the cell membranes of neurons located in the
NAc and the hippocampus [22].
The process, as described by Blum and Kozlowski [1],
starts in the hypothalamus with the excitatory activity of
serotonin-releasing neurons. This causes the release of the
opioid peptide met-enkephalin in the ventral tegmental
area, which inhibits the activity of neurons that release the
inhibitory neurotransmitter gamma-aminobutyric acid
(GABA). The disinhibition of dopamine-containing neu-
rons in the ventral tegmental area (VTA) allows them to
release dopamine in the NAc and (via amygdala) in cer-
tain parts of the hippocampus, permitting the completion
of the cascade and the development of the reward sensa-
tion [23]. Usually, if the cascade is working properly, the
reward or feeling of "well-being", or FGR, is obtained pro-
vided certain basic conditions are fulfilled [1].
RDS and genetic antecedents
Understanding the brain reward cascade provides insight
into the development of a blue-print for unlocking certain
candidate genes and polymorphisms that could impact
the brain in a negative manor. Impairment of the brain
reward cascade ultimately leads to a reduction of net DA
release, a reduction in dopamine receptors and as such an
enhancement of substance craving activity. While there
are many genes involved, it has been adequately estab-
lished that polymorphisms of the serotonergic- 2 A recep-
tor (5-HTT2a); dopamine D2 receptor (DRD2) and the
Catechol-o-methyl-transferase (COMT) genes predispose
individuals to aberrant RDS behaviors especially cravings
[19,71]. In the case of both serotonin and dopamine gene
polymorphisms, their respective receptors are signifi-
cantly lower than normal [24,25]. A certain type of poly-
morphism in the COMT gene results in an increase in the
catabolism of synaptic DA and subsequent reduced func-
tion [26]. Polymorphic identification of at least these
three genes provides insight into a genetic window of an
impaired brain reward cascade that places that individual
at high risk for excessive craving behaviors. Based on a
published [27] mathematical "Bayesian" approach, it was
found that individuals carrying these known polymor-
phisms (in particular the DRD2) have a 74% chance that
given the trigger of environmental insult will develop RDS
(for reviews see [1,18-21]).
Role of dopamine agonists in proliferation of D2 
receptors
Studies in vitro have shown that constant stimulation of
DA receptors by agonists result in proliferation of
Dopamine D2 receptors coupled to G proteins. Specifi-
cally it was shown [28,29] in transfected kidney cells and
expressed in Spodoptera frugiperda insect cells that stimula-
tion of DA receptors by the pure D2 receptor agonist Bro-
mocriptine resulted in proliferation of D2 receptors over
a 14 day period. In the same study it was shown that
administration of a DA antagonist caused the prolifera-
tion of D2 antagonist receptors as well. These two inde-
pendent effects suggest that environmental manipulation
in spite of genetic antecedents will result in receptor pro-
liferation. This can best be explained by the understand-
ing that agonist activity involves the stimulation of the
mRNA that is involved in transcription. Activation of the
DRD2/mRNA results in a negative feedback that promotes
an enhancement of mRNA directed D2 receptor prolifera-
tion. This fact becomes very important when coupled with
the findings that an increase in substance seeking is due to
a paucity of DA D2 receptors [24,25]. Therefore, if low D2
receptors equate to increased craving behavior then an
increase in D2 receptors should result in attenuation ofTheoretical Biology and Medical Modelling 2008, 5:24 http://www.tbiomed.com/content/5/1/24
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brain reward cascade [1] -modified with permission from Gene Therapy Press Figure 1
Brain reward cascade [1]-modified with permission from Gene Therapy Press. In this cascade, stimulation of the ser-
otonergic system in the hypothalamus leads to the stimulation of delta/mu receptors by serotonin to cause a release of 
enkephalins. Activation of the enkephalinergic system induces an inhibition of GABA transmission at the substantia nigra by 
enkephalin stimulation of mu receptors at GABA neurons. This inhibitory effect allows for the fine tuning of GABA activity. 
This provides the normal release of dopamine at the projected area of the n. accumbens (reward site of the brain). It is note-
worthy that other important neurotransmitters and receptors are involved such as endocannibinoids and glutamate.Theoretical Biology and Medical Modelling 2008, 5:24 http://www.tbiomed.com/content/5/1/24
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craving behavior. Our solution is to stimulate DA release
at the NAc naturally, not via powerful DA agonists that
could ultimately lead to DA down-regulation. Whereas
DA activation could occur with targeted pharmaceuticals
such as Bromocriptine or other DA agonists [30], we pre-
fer a more natural approach developed to mimic the brain
reward cascade; in essence, through the utilization of pre-
cursor amino-acids and simultaneous enkephalinase/
COMT inhibition, which we suggest will systematically
induce natural release of DA without side effects.
Traditional anti-craving treatments block 
dopamine activity at the brain reward centers
Most recent examples of pharmaceuticals that block DA
release and or receptor activation include Acomplia
(Rimonabant), the cannabinoid (CB1) receptor blocker
and possibly Gabapentin. While there are numerous stud-
ies supporting the therapeutic benefits of Acomplia as an
anti-craving drug the long term adverse effects resulted in
a recent rejection by the United States Federal Drug
Administration (FDA). A recent PUBMED search revealed
1007 papers on Acomplia. Since the prevalence of obesity
continues to increase, there is a demand for effective and
safe anti-obesity agents that can produce and maintain
weight loss and improve comorbidity. Christensen et al
[31] did a meta-analysis of all published randomized con-
trolled trials to assess the efficacy and safety of the newly
approved anti-obesity agent Rimonabant. They searched
the Cochrane database and Controlled Trials Register,
Medline via Pubmed, Embase via WebSpirs, Web of Sci-
ence, Scopus, and reference lists up to July, 2007. They
collected data from four double-blind, randomized con-
trolled trials (including 4105 participants) that compared
20 mg per day Rimonabant with placebo. Patients given
Rimonabant had a 4.7 kg (95% CI 4.1–5.3 kg; p < 0.0001)
greater weight reduction after 1 year than did those given
placebo. Rimonabant caused significantly more adverse
events than did placebo (Odds Ratio (OR) = 1.4; p =
0.0007; number needed to harm = 25 individuals [95% CI
17–58]), and 1.4 times more serious adverse events (OR =
1.4; p = 0.03; number needed to harm = 59 [27–830]).
Patients given Rimonabant were 2.5 times more likely to
discontinue the treatment because of depressive mood
disorders than were those given placebo (OR = 2.5; p =
0.01; number needed to harm = 49). Furthermore, anxiety
caused more patients to discontinue treatment in
Rimonabant groups than in placebo groups (OR = 3.0; p
= 0.03; number needed to harm = 166). Their findings
suggest that 20 mg per day of Rimonabant increases the
risk of adverse psychiatric events – i.e. depressed mood
disorders and anxiety; despite depressed mood being an
exclusion criterion in these trials. Taken together with the
recent US Food and Drug Administration finding of
increased risk of suicide during treatment with Rimona-
bant, these researchers recommend increased alertness by
physicians to these potentially severe psychiatric adverse
reactions. Concerning this report, we propose that the
negative effects on mood are due to the continued block-
ade of naturally required DA release at the NAc.
Gabapentin is a gamma-aminobutyric acid (GABA) ana-
logue, with GABAmimetic pharmacological properties.
Gabapentin is used for the treatment of seizures, anxiety
and neuropathic pain. It has been proposed that Gabap-
entin may be useful in the treatment of cocaine depend-
ence. However, clinical trials with Gabapentin have
shown conflicting results, while preclinical studies are
sparse. In one study, Peng et al [32] investigated the effects
of Gabapentin on intravenous cocaine self-administration
and cocaine-triggered reinstatement of drug-seeking
behavior, as well as on cocaine-enhanced DA in the NAc.
They found that Gabapentin (25–200 mg/kg, i.p., 30 min
or 2 h prior to cocaine) failed to inhibit intravenous
cocaine (0.5 mg/kg/infusion) self-administration under a
fixed-ratio reinforcement schedule or cocaine-triggered
reinstatement of cocaine-seeking behavior. In vivo micro-
dialysis showed that the same doses of Gabapentin pro-
duced a modest increase (approximately 50%, p < 0.05)
in extracellular NAc GABA levels, but failed to alter either
basal or cocaine-enhanced NAc DA. These data suggest
that Gabapentin is a weak GABA-mimic drug. At the doses
tested, it has no effect in the addiction-related animal
behavioral models. This is in striking contrast to positive
findings in the same animal models shown by another
GABAmimetic – gamma-vinyl GABA – by Garner's group
(see [18] for review). Based on our current theoretical
model we are opposed to the use of Gabapentin to treat
substance seeking behavior especially in long term care.
Other than a few scientific groups that suggest serotoner-
gic/dopaminergic agonist therapy [33], most strategies
embrace dopaminergic receptor blockade/attenuation of
dopamine release [2,3,18-21]. We propose that, in most
circumstances, utilization of amino acid precursors affect-
ing positive dopaminergic activation is a better alternative
[34-48] (see tables 1 &2).
Amino acid therapy as an anti-craving agent
Although DA release (and/or DA receptor binding) could
in theory be potentiated by the above proposed ingredi-
ents (summarized in table 1) for dopaminergic activation,
no one to date has actually shown this important poten-
tial and is the subject of future intensive investigation.
However indirect support is derived from the effects
obtained with these ingredients in a number of clinical tri-
als over two decades (see table 1).
Table 1 illustrates the anti-craving and other effects
observed with the Synaptamine™ complex. Other more
recent published clinical trials include:Theoretical Biology and Medical Modelling 2008, 5:24 http://www.tbiomed.com/content/5/1/24
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Table 1: Summary of completed clinical studies with nutraceutical supplementation: a literature review
Drug Abused or 
Dysfunction
Supplement Used No. of Patients No. of Days Study Type Significant Results Publication
Alcohol SAAVE 22 28 TO
IP
100% decrease in BUD 
scores. Detoxification 
measures: reduction in 
benzodiazepine 
requirement, reduction in 
withdrawal tremors after 
72 hours, reduction in 
depression
Blum K, Trachtenberg MC, 
Ramsey J. Improvement of 
inpatient treatment of the 
alcoholic as a function of 
neuronutrient restoration: 
a pilot study. Int J Addiction. 
1988; 23:991–98.
Blum K, Trachtenberg MC. 
Neurogenic deficits caused 
by alcoholism: restoration 
by SAAVE. Journal of 
Psychoactive Drugs. 1988; 
20:297.
Alcohol plus 
Polydrugs
SAAVE 62 21 DBPC
IP
Reduction in psychosocial 
stress reduction as 
measured by SCL, reduced 
BESS score, improved 
physical score, six-fold 
decrease in likelihood of 
leaving AMA after five days.
Blum et al. Enkephalinase 
inhibition and precursor 
amino acid loading 
improves inpatient 
treatment of alcoholics and 
poly-drug abusers: a 
double-blind placebo-
controlled study of the 
neuronutrient intervention 
adjunct SAAVE. Alcohol. 
1989; 5:481.
Cocaine Tropamine 54 30 TO
IP
Drug hunger significantly 
reduced in patients taking 
SAAVE as compared to 
controls; 4.2 percent AMA 
rate for patients on 
Tropamine versus 28 
percent for patients on 
SAAVE and 37 percent for 
controls. </SPAN>
Blum et al. Reduction of 
both drug hunger and 
withdrawal against advice 
rate of cocaine abusers in a 
30 day inpatient treatment 
program with the 
neuronutrient tropamine. 
Curr Ther Res. 1988; 
43:1204.
Alcohol and 
Cocaine
SAAVE and 
Tropamine
60 379 TO
CP
At end of one year over 50 
percent of the alcoholic 
DUI offenders not using 
SAAVE dropped out of the 
program while less than 15 
percent of those using 
SAAVE dropped out. For 
the cocaine abusers over 
90 percent of the Non-
Tropamaine group 
dropped out, but less than 
25 percent of the patients 
in the control group.
Brown et al. 
Neurodynamics of relapse 
prevention: a neuronutrient 
approach to outpatient DUI 
offenders. J. Psychiatric 
Drugs. 1990; 22:173.Theoretical Biology and Medical Modelling 2008, 5:24 http://www.tbiomed.com/content/5/1/24
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Over-Eating PCAL 103 27 90 TO
OP
The PCAL 103 group lost 
an average of 27 pounds in 
90 days compared with an 
average loss of 10 pounds 
for the control group. Only 
18.2 percent of the PCAL 
103 patient group relapsed 
compared to 82 percent of 
the patients in the control 
group.
Blum et al.20 
Neuronutrient effects on 
weight loss on 
carbohydrate bingeing in a 
bariatric setting. Curr Ther 
Res. 1990; 48:2a17.
Over-Eating PCAL 103 247 730 PCOT
OP
After two years, craving 
and binge eating were 
reduced one-third in group 
of patients on PCAL 103, 
as compared to the control 
patients. PCAL 103 group 
regained 14.7 pounds of 
their lost weight compared 
with 41.7 percent weight 
regained in control 
patients.
Blum K, Cull JG, Chen JHT, 
Garcia-Swan S, Holder JM, 
Wood R, et al. Clinical 
relevance of PhenCal in 
maintaining weight loss in 
an open-label, controlled 2-
year study. Curr Ther Res. 
1997; 58:745–63.
Over-Eating Chromium 
Picolinate (CP) and 
L-Camitine
40 112 RDBPC
CP
21 percent increase (p < 
0.001) in resting metabolic 
rate (RMR), no change in 
lean body mass (LBM), 
RMR:LBM increased 25 
percent (p < 0.001). Body 
fat decreased 
approximately 1.5 lbs./
week, and reduction in 
serum cholesterol while 
incre asing RMR with no 
loss of LBM
Kaats FE et al. The short-
term therapeutic effect of 
treating obesity with a plan 
of improved nutrition and 
moderate caloric 
restriction. Curr Ther Res. 
1992; 51:261.
Over-Eating Chromium 
Picolinate
32 180 DBPC
OP
After six months the CrP 
group had an increase in 
lean body mass and 
avoided non-fat related 
weight loss. Difference 
between groups was 
significant at p < 0.001.
Bahadori B, Habersack S, 
Schneider H, Wascher TC, 
Topiak H. Treatment with 
chromium picolinate 
improves lean body mass in 
patients following weight 
reduction. Federation Am 
Soc Exp Bio 1995.
Over-Eating Chromium 
Picolinate
154 72 RDBPC OP 200 and 400 mcg of CrP 
brought about significant 
changes in Body Mass 
composition indicies when 
compared with placebo
Kaats FE, Blum K, Fisher JA, 
Aldeman JA. Effects of 
chromium picolinate 
supplementation on body 
mass composition: a 
randomized, double-blind, 
placebo-controlled study. 
Curr Ther Res. 1996; 
57:747–56
Table 1: Summary of completed clinical studies with nutraceutical supplementation: a literature review (Continued)Theoretical Biology and Medical Modelling 2008, 5:24 http://www.tbiomed.com/content/5/1/24
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Over-Eating Chromium 
Picolinate
122 90 RDBPC
OP
After controlling for 
differences in caloric 
expenditure and caloric 
intake as compared with 
the placebo group, 400 
mcg CrP group lost 
significantly more weight (p 
< 0.001) and body fat (p < 
0.004), had a greater 
reduction in body fat (p < 
0.001), significantly 
improve body composition 
(p < 0.004).
Kaats FE, Blum K, Pullin D, 
Keith SC, Wood R. A 
randomized double-masked 
placebo-controlled study of 
the effects of chromium 
picolinate supplementation 
on body composition: a 
replication of previous 
study. Curr Ther Res. 1998; 
59:379–88.
Over-Eating Chromium 
Picolinate
122 90 RDBPC
OP
Measures of changes in fat 
weight, change in body 
weight, percent change in 
weight, and body weight 
changes in kgms were all 
significant in A2/A2 group, 
and non-significant in A1/
A2 and A1/A1 carriers.
Blum K, Kaats G, Eisenbery 
A, Sherman M, Davis K, 
Comings DE, Cull JG, Ch 
en THJ, Wood R, Bucci L, 
Wise JA, Braverman ER, 
and Pullin D. Chromium 
Picolinate Induces Changes 
in Body Composition as a 
Function of the Taq1 
Dopamine D2 Receptor A1 
Alleles. Submitted to 
International J. Eat. Dis.
Over-Eating Chromium 
Picolinate and 
Chromium 
Picolinate 
comparison
43 63 ROTPC
OP
CrP supplementation 
resulted in significant 
weight gain, while exercise 
training combined with 
CrP supplementation 
resulted in significant 
weight loss and lowered 
insulin response to an oral 
glucose load. Concluded 
high levels of CrP 
supplementation are 
contraindicated for weight 
loss, in young obese 
women. Moreover, results 
suggested that exercise 
combined with CrP 
supplementation may be 
more beneficial than 
exercise training alone for 
modification of certain 
CAD or NIDDM risk 
factors
Grant KE, Chandler RM, 
Castle AL, Ivy JL. 
Chromium and exercise 
training: effect on obese 
women.20J Am Sports Med 
1997; 29(8):992–8.
Healthy 
Volunteers
Tropagen 15 30 DBPC
OP
Non-drug subjects with 
Tropagen performed 
better on computer 
memory and performance 
tasks as measured with 
P300 wave evoked 
potential. Changes in P300 
wave evoked potential 
result in better focusing 
ADHD patients
Defrance JJ, Hymel C, 
Trachtenberg MC et al. 
Enhancement of attention 
processing by Kantrol in 
healthy humans: A pilot 
study. Clin Electroencephalgr. 
1997; 28:68–75.
Abbreviations used: BUD – building up to drink; AMA – withdrawal against medical advice; OP – outpatient; MMPI – Minnesota Multiphasic 
personality inventory; DB – double-blind; IP – inpatient; SCL – skin conductance level; BESS – behavioral, emotional, social, spiritual; DBPC – 
double-blind placebo-controlled; DUI – driving under the influence; R – randomized; TO – open trial
Source : Chen et al 2004 [39]with permission Elsevier.
Table 1: Summary of completed clinical studies with nutraceutical supplementation: a literature review (Continued)Theoretical Biology and Medical Modelling 2008, 5:24 http://www.tbiomed.com/content/5/1/24
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1. In a one year open trial consisting of 600 patients mod-
erate to severe alcoholics utilization of both Oral and IV
forms of Synaptamine resulted in significant reduction in
cravings; reduced depression, reduced anxiety; reduced
anger; reduced fatigue; reduced lack of energy, and
reduced crisis [36].
2. In a one year open trial consisting of 76 patients severe
poly drug addicts utilization of oral forms of Synaptamine
resulted in significant attenuation of drug cravings;
reduced relapse; reduced stress; reduced depression;
reduced anger; and increased energy. The drop- out rate
for alcoholics was only 7% [40].
3. In a one year cross sectional open trial study of 24
unscreened individuals utilization of oral Synaptamine
variant resulted in the following benefits: stress reduction;
sleep enhancement; increase in energy level; generalized
well-being; reduction in cravings (sweets/carbs); improve-
ment in mental focus/memory; improvement in blood
sugar levels; reduction in food consumption; loss of
inches around waist; loss of weight; reduction in blood
pressure; improvement in workout performance; reduc-
Table 2: Amino acid nutrition therapy
Supplemental 
Ingredient
Restored Brain 
Chemical
Addictive Substance 
Abuse
Amino Acid Deficiency 
Symptoms
Expected Behavior 
Change
D-Phenylalanine or DL-
Phenylalanine
Enkephalins, Endorphins Heroin, Alcohol, Marijuana, 
Sweets, Starches, 
Chocolate, Tobacco
Most Reward Deficiency 
Syndrome (RDS) 
conditions sensitive to 
physical or emotional pain. 
Crave comfort and 
pleasure. Desire certain 
food or drugs. D-
Phenylalaine is a known 
enkephalinease inhibitor.
Reward stimulation. Anti-
craving. Mild anti-
depression. Mild improved 
energy and focus. D-
Phenylalaine promontes 
pain relief, increases 
pleasure.
L-Phenylalanine or L-
Tyrosine
Norepinephrine, 
Dopamine
Caffeine, Speed, Cocaine, 
Marijuana, Aspartame, 
Chocolate, Alcohol, 
Tobacco, Sweets, Starches
Most RDS conditions. 
Depression, low energy. 
Lack of focus and 
concentration. Attention-
deficit disorder.
Reward stimulation. Anti-
craving. Anti-depression. 
Increased energy. 
Improved mental focus.
L-Tryptophan or 5 
hydroxytryptophan (5HTP)
Serotonin Sweets, Alcohol, Starch, 
Ecstasy, Marijuana, 
Chocolate, Tobacco
Low self esteem. 
Obsessive/compulsive 
behaviors. Irritability or 
rage. Sleep problems. 
Afternoon or evening 
cravings. Negativity. Heat 
intolerance. Fibromyalgia. 
Seasonal affective disorder.
Anti-craving. Anti-
depression. Anti-insomnia. 
Improved appetite control. 
Improvement in all mood 
and other serotonin 
deficiency syndromes.
Gamma-amino butyric acid 
(GABA)
GABA Valium, Alcohol, Marijuana, 
Tobacco, Sweetes, 
Starches
Feeling of being stressed 
out. Nervous. Tense 
muscles. Trouble relaxing.
Promotes calmness. 
Promotes relaxation.
L-Glutamine GABA (mild enhancement). 
Fuel source for entire brain
Sweets, Starches, Alcohol Stress. Mood swings. 
Hypoglycemia.
Anti-craving, anti-stress. 
Levels blood sugar and 
mood. GABA (mild 
enhancement). Fuel source 
for entire brain.
Table 2 Comments: Rhodiola rosea has been added to the formula and is a known Catechol-O-methyl transferase (COMT) inhibitor. This 
provides more synaptic dopamine in the VTA/NAc.
Source: Perfumi M, Mattioli L. Adaptogenic and central system effects of single doses of 3% rosavin and 1% salidroside Rhodiola rosea L. extract in 
mice. Phytother Res. 21 2007 37–43
Chromium salts – This has been added to the formula to enhance insulin sensitivity and resultant brain concentration of serotonin.
Note: To assist in amino acid nutritional therapy, the use of a multivitamin/mineral formula is recommended. Many vitamins and minerals serve as 
co-factors in neurotransmitter synthesis. They also serve to restore general balance, vitality and well-being to the RDS patient who typically is in a 
state of poor nutritional health. The utilization of GABA is limited due to its polar nature and ability to cross the blood brain barrier. Glutamate is 
used in a low level only to prevent over-inhibition of enkephalin breakdown and subsequent inhibition of GABAergic spiny neurons of the substantia 
nigra.Theoretical Biology and Medical Modelling 2008, 5:24 http://www.tbiomed.com/content/5/1/24
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tion in drug seeking behavior ; reduction in hyperactivity;
reduction in cholesterol levels [37].
4. In a subset of 27 individuals out of 1000 self-identified
obese subjects geneotyped for polymorphisms of the
DRD2 gene and of those carrying the Taq A1 allele had a
significant Pearson correlation with days on treatment
compared to the A2 carriers. For the DRD2A1 carriers the
number of days on Synaptamine Complex (variant
changed according to geneotyping a total of five candidate
genes) was 110 compared to only 52 days in A2 probands
suggesting that DRD2 genotype can predict treatment
compliance [76].
5. In a subset of 27 individuals out of 1000 self-identified
obese subjects geneotyped for polymorphisms of the
DRD2, PPAR gamma 2, MTHDFR, 5-HT2a genes and sub-
sequently provided a customized Synaptamine variant
based on polymorphisms the following significant results
were obtained: weight loss; sugar craving reduction; appe-
tite suppression; snack reduction; reduction in late night
bingeing; increased perception of over-eating; increased
energy; enhanced quality of sleep; and increased happi-
ness [77].
Table 2 provides a list of proposed ingredients for
dopaminergic activation.
The result of utilizing this natural dopaminergic activating
approach over time should lead to neuronal DA release at
the NAc, potentiating a proliferation of D2 receptors
[28,29]. Moreover, support in humans is derived from
anti-craving effects observed in numerous peer reviewed
published clinical trials including randomized double-
blind placebo controlled studies [34-48] (see also Table
2). It is noteworthy that animal gene therapy utilizing
cDNA vectors of the DRD2gene implanted into the NAc
results in decrease alcohol craving behavior [49]. We are
cognizant that the dopaminergic activation approach
should be utilized to treat not only alcohol, cocaine and
nicotine cravings, but glucose craving as well. Thus the
coupling of genetic antecedents and nutrition may be a
very viable alternative approach for the treatment of obes-
ity.
Nutrigenomics of obesity: a case study
Obesity-related medical conditions are the second leading
cause of death in the U.S. Classified as a chronic disease in
1985, the understanding of obesity and its causes and
effects has been further elucidated through additional
research into the genetic and biologic factors influencing
this deadly disease. What used to be understood as prima-
rily a behavioral problem of overeating and under-exercis-
ing has only contributed to continued increases in the
rates of obesity despite increases in dieting, exercise and
the understanding of genes [50]. Successful strategies to
induce sustainable fat loss and manage obesity effectively
have been elusive. For the most part, the tactics employed
have not been multi-faceted, multi-system approaches,
but have been characterized by one-dimensional meta-
bolic approaches (e.g. cannabinoid (CB1) receptor block-
ade; serotonin receptor stimulation) targeted at achieving
weight loss as measured by linear criteria (i.e. scale weight,
Body Mass Index (BMI), percent body fat, etc).
Recent evidence indicates a much more complex and mul-
tidimensional syndrome, characterized by the simultane-
ous breakdown of many facets of metabolism exacerbated
or limited by the predispositions of inherited genetic traits
[51,52]. There is significant evidence to substantiate the
existence of RDS as a new paradigm shift in the under-
standing of Obesity [53]. Specifically, there are genetic
links to the various roles of catecholaminergic-influenced
pathways in aberrant substance seeking behavior, in par-
ticular cravings for carbohydrates [14,50,53,54]. We pro-
pose that these various neurological factors involved in
the etiology of obesity, regulated by genetic predisposi-
tions, are a subtype of RDS. The treatment of obesity and
or metabolic syndrome genomic mechanisms may pave
the way for novel prescription pharmaceuticals as well as
nutritional and/or nutraceutical therapies. There is grow-
ing evidence to support the augmentation of precursor
amino acid therapy and enkephalinase and COMT inhibi-
tion leading to enhanced levels of neurotransmitters: sero-
tonin, enkephalins, GABA and dopamine/
norepinephrine [26]. Utilizing the combination of
nutraceuticals directed at replenishing the nutrigenomic
needs of multiple pathways, including brain reward/met-
abolic targets, mechanistically mimicking the brain
reward cascade as well as fat regulation and cell repair
(DRD2, 5-HTT2a. PPAR-Gamma, MTHFR and Leptin
genes) will provide significant anti-obesity benefits
[1,19,20,22,34,35].
Our laboratory recently presented evidence to support the
significant benefits of a DNA-directed personalized
weight management solution ([34,35]; see table 2). We
are proposing potential mechanisms herein, along with
the rationale for utilizing this multifaceted approach to
attenuate the pleiotropic defaults in obesity as well as
other addictions including alcohol, cocaine and nicotine.
In this regard, preliminary testing for the first time seems
to support a combination of neurotransmitter precursor
amino acids, enkephalinase inhibition, and catecho-
lamine 0-methyl-transferase (C.O.M.T.) inhibition ther-
apy. Components of a nutrigenomic formula are
modified based on the identification of specific gene pol-
ymorphisms resulting from genomic testing and the deter-
mination of correct dosage levels to promote successfulTheoretical Biology and Medical Modelling 2008, 5:24 http://www.tbiomed.com/content/5/1/24
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and sustainable results in improved body recomposition
[55,56].
In summary, the impact of biomics technology and the
DNA directed nutraceutical targeting of the brain reward
circuitry may provide a customized approach to prevent
and treat high risk individuals who are carriers of a genetic
predisposition to obesity and related RDS behaviors.
While over 600 genes have been associated with obesity,
we believe that selective candidate genes could provide
useful information. Thus, we present the necessity of
exploiting systems biology and "omics" [34].
Relapse in addiction: anti-reward
"A neurobiological model of the brain emotional systems
has been proposed to explain the persistent changes in
motivation that are associated with vulnerability to
relapse in addiction, and this model may generalize to
other psychopathology associated with dysregulated
motivational systems" [57]. Addiction is conceptualized
as a cycle of decreased function of brain reward systems
and recruitment of antireward systems that progressively
worsen, resulting in the compulsive use of drugs. This
concept is similar to our concept of RDS which is counter
to the normal homeostatic limitation of reward function.
According to Koob and La Moal [57] "counteradaptive
processes, such as opponent processes that are part of the
normal homeostatic limitation of reward function, fail to
return within the normal homeostatic range and are
hypothesized to repeatedly drive the allostatic state. Exces-
sive drug taking thus results in not only the short-term
amelioration of the reward deficit but also suppression of
the antireward system. However, in the long term, there is
worsening of the underlying neurochemical dysregula-
tions that ultimately form an allostatic state (decreased
dopamine and opioid peptide function, increased cortico-
tropin-releasing factor activity). This allostatic state is
hypothesized to be reflected in a chronic deviation of
reward set point that is fueled not only by dysregulation
of reward circuits per se but also by recruitment of brain
and hormonal stress responses. Vulnerability to addiction
may involve genetic comorbidity (i.e. DRD2 gene A1
allele etc.) and developmental factors at the molecular,
cellular, or neurocircuitry levels that sensitize the brain
antireward systems."
Moreover, others have described relapse in specific terms
emphasizing the importance of dopaminergic function.
Volkow et al. [58] suggested that drug addiction is charac-
terized by a set of recurring processes (intoxication, with-
drawal, craving) that lead to the relapsing nature of the
disorder. These researchers have used positron emission
tomography to investigate in humans the role of
dopamine (DA) and the brain circuits it regulates in these
processes. They have shown that increases in DA are asso-
ciated with the subjective reports of drug reinforcement
corroborating the relevance of drug-induced DA increases
in the rewarding effects of drugs in humans. During with-
drawal they have shown significant reductions in DA D2
receptors and in DA release in drug abusers. They have
supported the original RDS concept [27] by postulating
that this hypodopaminergic state would result in a
decreased sensitivity to natural reinforcers, perpetuating
the use of the drug as a means to compensate for this def-
icit and contributing to the anhedonia and dysphoria seen
during withdrawal. Because the D2 reductions are associ-
ated with decreased activity in the anterior cingulate gyrus
and in the orbitofrontal cortex they postulate that this is
one of the mechanisms by which DA disruption leads to
compulsive drug administration and the lack of control
over drug intake in the drug-addicted individual. This is
supported by studies showing that during craving these
frontal regions become hyperactive in proportion to the
intensity of the craving. Therefore, Volkow et al [58] pos-
tulate that dopamine contributes to addiction by disrupt-
ing the frontal cortical circuits that regulate motivation,
drive, and self-control.
Linking attention deficit disorder with obesity 
and dopamine
It is noteworthy that our laboratory has proposed that
Attention Deficit Disorder (ADHD) is a subtype of RDS,
having dopaminergic allelic associations among other
deficit genes. In fact, being carriers of specific polymor-
phisms of the dopaminergic system places these individu-
als, both children and adults, at high risk for RDS
behaviors (i.e. Substance Use Disorder [SUD] etc.)
[59,60]. The linking of ADHD and obesity via a dopamin-
ergic mechanism has also been proposed by others
[61,62]. There is strong evidence indicating that
dopamine dysregulation is very important in the patho-
physiology of ADHD, as well as in the mechanism of the
therapeutic action of stimulant drugs. With regard to ther-
apeutic implications, recent studies indicate that methyl-
phenidate (MPH), a drug widely used for ADHD, reduced
overall energy intake with a selective reduction in dietary
fat [61]. The findings are consistent with a reward defi-
ciency model [34] of obesity whereby low brain
dopamine predicts overeating and obesity, and adminis-
tering agents that increase dopamine results in reduced
feeding behavior. The obesity epidemic has focused atten-
tion on obesity's health consequences beyond cardio-vas-
cular disease and diabetes. Current findings link both
obesity and ADHD to the dopamine system and implicate
dopamine genes in body weight, eating, and ADHD,
among others. Detailed consideration suggests that
dopaminergic changes in the prefrontal cortex among
individuals with the ADHD subtype Attention Deficit Dis-
order (ADD) may increase their risk for obesity. Thus,
individuals and populations with a high prevalence ofTheoretical Biology and Medical Modelling 2008, 5:24 http://www.tbiomed.com/content/5/1/24
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hypodopaminergic genes may experience higher rates of
obesity in the presence of abundant food [62]. From an
evolutionary perspective, Campbell and Eisenberg [62]
suggest that alterations in the dopamine system appear to
affect a wide range of behavioral phenotypes. They suggest
that recent evolutionary changes in the dopamine recep-
tor genes selected to increase cognitive and behavioral
flexibility may now be associated with attention problems
and increased food consumption in an obesity gene envi-
ronment.
With this said we must consider these results with caution,
especially in terms of in vivo studies by Chen et al [63]
showing a down-regulation of D2 receptor density follow-
ing a 6 day infusion of the D2 agonist quinpirole [64].
Interestingly, continuous infusion of quinpirole caused a
significant down-regulation of striatal D2 dopamine
receptors without significantly changing the density of D1
receptors. This was accompanied by a decrease in the level
of D2 receptor messenger RNA in the striatum as meas-
ured by northern blotting. The down-regulation of
dopamine receptors was selective for D2 dopamine recep-
tors. Moreover, continuous treatment with quinpirole
resulted in a significant increase in striatal mu opioid
receptor levels without significant change in the delta opi-
oid receptors. This treatment also induced a significant
decrease in proenkephalin messenger RNA in the stria-
tum. Taken together, these results suggest that the down-
regulation of D2 dopamine receptor and D2 receptor mes-
senger RNA is the result of the persistent stimulation of
D2 receptors and that the up-regulation of mu opioid
receptors may be a compensatory response to a decreased
biosynthesis of enkephalin. While this appears at first
sight to contradict our suggestion, we theorize that the dif-
ference in continuous stimulation by a slow (more physi-
ological and natural) release of DA, as proposed herein,
will result in a proliferation in D2 receptors as seen in the
in vitro studies [28,29] and documented by the consistent
anti-craving effects observed in clinical trials [18,34-49].
It is noteworthy that diminished DA receptors are not
inevitably associated with depression or addictive behav-
iors. In fact, while the lower incidence of Parkinson's dis-
ease (PD) among smokers may be explained by a
protective effect of cigarette smoke, or by a tendency to
avoid addictive behaviors among future PD cases, this
does not hold true for alcoholism. Hernan et al [64] con-
ducted an indirect test of the latter hypothesis by compar-
ing the incidence of PD between alcoholics and
nonalcoholics in the General Practice Research Database
of the United Kingdom. Their case-control study included
1,019 cases and 10,123 matched controls. Overall, they
did not find a lower incidence of PD among alcoholics
compared with nonalcoholics (odds ratio: 1.09; 95 % CI:
0.67, 1.78). However, the contrary made be true. In Par-
kinson's disease, dopamine dysregulation syndrome
(DDS) is characterized by severe dopamine addiction and
behavioral disorders such as manic psychosis, hypersexu-
ality, pathological gambling, and mood swings or Reward
Deficiency Syndrome, as reported by Linazaroso et al [65].
In this regard, Witjas et al [66] describe the case of 2 young
parkinsonian patients suffering from disabling motor
fluctuations and dyskinesia associated with severe DDS.
In addition to alleviating the motor disability in both
patients, subthalamic nucleus (STN) deep brain stimula-
tion greatly reduced the behavioral disorders as well as
completely abolishing the addiction to dopaminergic
treatment. According to the authors [66], dopaminergic
addiction in patients with Parkinson's disease therefore
does not constitute an obstacle to high-frequency STN
stimulation, and this treatment may even cure the addic-
tion. These findings related to Parkinson's disease partly
support our proposal herein.
There is an abundance of studies showing that acute
blockade of DA receptors will result in an attenuation of
substance seeking as in the case observed for the Cannab-
inoid CB1 receptor antagonist, Rimonabant, which neu-
ronal blocks DA-release [67]. This and other work has
prompted Berridge [68] to rethink the role of DA as a so
called "well-being substance". According to Berridge there
are three competing explanatory categories: 'liking,' learn-
ing, and 'wanting.' Does dopamine mostly mediate the
hedonic impact of reward ('liking')? Does it instead mead-
iate learned predictions of future reward, and stamp in
associative links (learning)? Or does dopamine motivate
the pursuit of rewards by attributing incentive salience to
reward-related stimuli ('wanting')? In this regard, recent
evidence indicates that dopamine is not needed for new
learning, and is not sufficient to mediate learning directly
by causing teaching or prediction signals. By contrast,
growing evidence indicates that dopamine does contrib-
ute causally to incentive salience. Dopamine appears nec-
essary for normal 'wanting', and dopamine activation can
be sufficient to enhance cue-triggered incentive salience.
Drugs of abuse that promote dopamine signals short-cir-
cuit and sensitize the dynamic mesolimbic mechanisms
that evolved to attribute incentive salience to rewards.
Such drugs interact with incentive salience integrations of
Pavlovian associative information with physiological
state signals. In short, dopamine's contribution appears to
be chiefly to cause 'wanting' for hedonic rewards, more
than 'liking' or learning for those rewards. Interestingly,
Alcaro et al [69] agree with Berridge's view by suggesting
that the rewarding properties of drugs of abuse are, in
part, caused by the activation of the "SEEKING" disposi-
tion, ranging from appetitive drive to persistent craving
depending on the intensity of the affect. The implications
of such a view for understanding addiction are consid-
ered, with particular emphasis on factors predisposingTheoretical Biology and Medical Modelling 2008, 5:24 http://www.tbiomed.com/content/5/1/24
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individuals to develop compulsive drug seeking behav-
iors. In our view this predisposition is genetic and
involves among other candidate genes the DRD2 gene.
One important example of hedonic "wanting" and or
"SEEKING" predisposition involves polymorphisms of
the DRD 2 gene [70]. Statistical analysis revealed a signif-
icant association between the DRD2 TaqI A genotypes and
"Eros" (a loving style characterized by a tendency to
develop intense emotional experiences based on physical
attraction to the partner), thus supporting hedonism as a
"wanting" or "SEEKING" phenomena. Exploiting this
view one might argue that the "reward center" be simpli-
fied and termed "the well-being system".
Summary
In brief, the site of the brain where one experiences feel-
ings of well being is the mesolimbic system. This part of
the brain has been termed the "reward center". The chem-
ical messages include serotonin, enkephalins, GABA and
dopamine, all working in concert to provide a net release
of DA at the NAc (a region in the mesolimbic system). It
is well known that genes control the synthesis, vesicular
storage, metabolism, receptor formation and catabolism
of neurotransmitters. The polymorphic versions of these
genes have certain variations, which could lead to an
impairment of the neurochemical events involved in the
neuronal release of DA. The cascade of these neuronal
events has been termed "Brain Reward Cascade". A break-
down of this cascade will ultimately lead to a dysregula-
tion and dysfunction of DA. Since DA has been
established as the "pleasure molecule" and the "anti-stress
molecule," any reduction in function could lead to reward
deficiency and resultant aberrant substance seeking
behavior. Our physiology is motivationally programmed
to drink, eat, have sex and desire pleasurable experiences.
Impairment of the mechanisms involved in these natural
processes leads to multiple impulsive, compulsive and
addictive behaviors governed by genetic polymorphic
antecedents. While there are a plethora of genetic varia-
tions at the level of mesolimbic activity, polymorphisms
of the serotonergic-2A receptor (5-HTT2a), dopamine D2
receptor (DRD2) and catechol-o-methyl-transferase
(COMT) genes predispose individuals to excessive crav-
ings and resultant aberrant behaviors. An umbrella term
to describe common genetic antecedents of multiple
impulsive, compulsive and addictive behaviors is RDS.
Individuals possessing a paucity of serotonergic and/or
dopaminergic receptors and a increased rate of synaptic
DA catabolism due to a high catabolic genotype of the
COMT gene are predisposed to self-medicating with any
substance or behavior that will activate DA release, includ-
ing alcohol, opiates, psychostimulants, nicotine, gam-
bling, sex, and even excessive internet gaming, among
others. Acute utilization of these substances induces a
feeling of well being. But unfortunately, sustained and
prolonged abuse leads to a toxic pseudo feeling of well
being resulting in tolerance and disease or discomfort.
Thus, low DA receptor levels consequent on carrying the
DRD2 A1 allelic genotype result in excessive cravings and
consequential behavior, whereas normal or high DA
receptors levels result in low craving-induced behavior. In
terms of preventing substance abuse, one goal would be to
induce a proliferation of DA D2 receptors in genetically
prone individuals. Experiments in vitro have shown that
constant stimulation of the DA receptor system via a
known D2 agonist results in significant proliferation of
D2 receptors in spite of genetic antecedents. In essence,
D2 receptor stimulation signals negative feedback mecha-
nisms in the mesolimbic system to induce mRNA expres-
sion, causing proliferation of D2 receptors. This molecular
finding serves as the basis for inducing DA release natu-
rally, also causing the same induction of D2-directed
mRNA and thus proliferation of D2 receptors in the
human. This proliferation of D2 receptors will in turn
induce the attenuation of craving behavior. In fact, as
mentioned earlier, this has been proven with work show-
ing DNA-directed overexpression (a form of gene therapy)
of the DRD2 receptors and significant reduction in alco-
hol craving-induced behavior in animals [50]. Finally, uti-
lizing long term dopaminergic activation will modify
behaviors including Substance Use Disorders (SUD),
Attention Deficit Hyperactivity Disorder (ADHD) and
Obesity among other reward deficient aberrant behaviors.
Support for the impulsive nature of individuals possessing
dopaminergic gene variants is derived from a recent article
suggesting that variants in the COMT gene predicts impul-
sive choice behavior, and may shed light on treatment tar-
gets [71].
A new but emerging concept provides a more comprehen-
sive understanding of reward behaviors and the role of
DA. In fact, interfering with accumbens DA appears par-
tially to dissociate the process of primary reinforcement
from processes regulating instrumental response initia-
tion, maintenance and selection [72]. The fact that DA in
the accumbens is involved with seeking maintenance sug-
gests that activating the DA system over long periods of
time rather than blocking DA receptors should result in
attenuation of substance seeking behavior. This idea does
not negate the important use of early detoxification
whereby opioid receptors are blocked with Naloxone
(Trexan/Rivera) [73], or DA activity is reduced with Acom-
posate [74] or with CB1 receptor blockers like Acomplia
[75] among other similar approaches. It is noteworthy
that assessment of 42 studies led to the conclusion that
short-term administration of naltrexone significantly
reduced the relapse rate, but was not associated with mod-
ification in the abstinence rate, suggesting the need for
additional approaches [74].Theoretical Biology and Medical Modelling 2008, 5:24 http://www.tbiomed.com/content/5/1/24
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We therefore suggest further that the biochemical and
molecular changes that take place in dopaminergic and
enkephalinergic systems following continuous neutraceu-
tical treatment with dopamine agonists may underlie the
mechanisms by which certain dopamine-mediated behav-
iors may be influenced. It is our intention to perform
micro-dialysis studies showing that precursor amino acid
therapy and enkephalinase inhibition induce DA release
at the nucleus accumbens of both animals and humans, as
well to perform additional clinical trials using nutrige-
nomic principles [76,77]. Finally our concept is supported
by other work involving glutamate neurotoxicity. Preincu-
bation with the D2 type dopamine agonists provides neu-
roprotection against glutamate neurotoxicity and the
protective effects blocked by a D2 antagonist, indicating
that D2 agonists provide protection mediated not only by
the inhibition of dopamine turnover, but also via D2 type
dopamine receptor [78]. While we caution interpretation
our laboratory is encouraged that long -term dopaminer-
gic agonistic therapy seems warranted.
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